Specialists & Providers
Diagnostic Biomarkers
Treatments & Interventions
Imipramine hydrochloride
substance
Imipramine pamoate
substance
Phenelzine sulfate
substance
Desipramine hydrochloride
substance
Nortriptyline hydrochloride
substance
Dibenzepin
substance
Methylphenidate hydrochloride
substance
Protriptyline hydrochloride
substance
Amitriptyline hydrochloride
substance
Trazodone hydrochloride
substance
Phenylalanine
substance
Fluoxetine hydrochloride
substance
Doxepin hydrochloride
substance
Lithium
substance
Trimipramine maleate
substance
Tranylcypromine sulfate
substance
Sertraline hydrochloride
substance
Paroxetine hydrochloride
substance
Quetiapine fumarate
substance
Venlafaxine hydrochloride
substance
Clinical Trials
Recent Trials
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
Real-World NeuroModulate: Investigating Non-Invasive Brain Stimulation for Neuropsychiatric Disorders at TUM
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
Integrating a Stepped Care Model of Screening and Treatment for Depression Into Malawi's National HIV Care Delivery Platform
Signs & Symptoms
Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.
Related Conditions
Quick Facts
- SNOMED CT
- 35489007
- UMLS CUI
- C0011581
- Fully Specified Name
- Depressive disorder (disorder)
- Specialists
- 2
- Diagnostic Biomarkers
- 3
- HPO Phenotypes
- 1
- Known Treatments
- 20
- Clinical Trials
- 48
Related Health Goals
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.